US Colorectal Cancer Drug Pipeline Analysis
Among all the regions affected with colorectal cancer, the US would continue to account for a giant’s share owing to its huge population base. With regards to rates of increase, it is most likely that the US would witness a modest increase in the prevalence of the disease, mostly as a result of the country having already reached epidemic proportions of the disease. According to estimates, approximately 55,000 people die of this type of cancer in the US every year. In 2013, close to 142,820 people new cases are estimated to be diagnosed with colorectal cancer, including 102,480 case of colon cancer and 40,340 cases of rectal cancer.
“US Colorectal Cancer Drug Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various drugs being developed for the treatment of Colorectal Cancer in US. Research report covers all the ongoing drugs being developed in various clinical development phases. This report enables pharmaceutical companies, collaborators and other associated stake holders to identify and analyze the available investment opportunity in the Colorectal Cancer drug market based upon development process. Following parameters for each drug profile in development phase are covered in “US Colorectal Cancer Drug Pipeline Analysis” research report:
- Drug Profile Overview
- Alternate Names for Drug
- Active Indication
- Phase of Development
- Mechanism of Action
- Brand Name
- Patent Information
- Country for Clinical Trial
- Owner / Originator/ Licensee/Collaborator
- Administrative Route
- Drug Class
- ATC Codes
- Research: 2
- Preclinical: 20
- Clinical: 2
- Phase-I: 16
- Phase-I/II: 12
- Phase-II: 42
- Phase-II/III: 2
- Phase-III: 7
- Marketed: 13
2. COLORECTAL CANCER DRUG CLINICAL PHASE: RESEARCH
2.1 Overview
2.2 Colorectal Cancer Drug Profile in Clinical Phase
3. COLORECTAL CANCER DRUG CLINICAL PHASE: PRECLINICAL
3.1 Overview
3.2 Colorectal Cancer Drug Profile in Clinical Phase
4. COLORECTAL CANCER DRUG CLINICAL PHASE: CLINICAL
4.1 Overview
4.2 Colorectal Cancer Drug Profile in Clinical Phase
5. COLORECTAL CANCER DRUG CLINICAL PHASE: PHASE-I
5.1 Overview
5.2 Colorectal Cancer Drug Profile in Clinical Phase
6. COLORECTAL CANCER DRUG CLINICAL PHASE: PHASE-I/II
6.1 Overview
6.2 Colorectal Cancer Drug Profile in Clinical Phase
7. COLORECTAL CANCER DRUG CLINICAL PHASE: PHASE-II
7.1 Overview
7.2 Colorectal Cancer Drug Profile in Clinical Phase
8. COLORECTAL CANCER DRUG CLINICAL PHASE: PHASE-II/III
8.1 Overview
8.2 Colorectal Cancer Drug Profile in Clinical Phase
9. COLORECTAL CANCER DRUG CLINICAL PHASE: PHASE-III
9.1 Overview
9.2 Colorectal Cancer Drug Profile in Clinical Phase
10. MARKETED
10.1 Overview
10.2 Marketed Colorectal Cancer Drug Profile
According to the American Cancer Society, Colorectal cancer (CRC) is the third most commonly diagnosed cancer, and the second most common cause of mortality amongst cancer patients in the US. According to estimates, approximately 55,000 people die of this type of cancer in the US every year. In 2013, close to 142,820 people new cases are estimated to be diagnosed with colorectal cancer, including 102,480 case of colon cancer and 40,340 cases of rectal cancer.
The treatment of this cancer is directly related to early diagnosis. It has been observed that with early diagnosis and treatment, there has been a remarkable improvement in the survival rates coupled with a reduction in the overall cost of patient treatment in the country. Though the mortality is declining in the US, owing to the introduction of CRC screening programs, there has been a rise in the rate of incidence because of diet and increasingly sedentary lifestyles.
Factors Driving Market
Patient Protection and Affordable Care Act, 2010: With the new coverage under the Patient Protection and Affordable Care Act of 2010, the financial disincentives liked to colorectal cancer screening process would be removed for a large segment of the population in the US. This would consequently lead to changes in reimbursement and thus the number of colorectal cancer screening procedures performed would be on a significant high in the next 2-3 years. This would drive the sales of many gastrointestinal endoscopy devices, including videoscopes and biopsy forceps.
Changes Insurance Policies: According to the health care act, all the new health insurance policies must cover preventative exams, including colonoscopies, without charging out-of-pocket fees such as copayments or deductibles. This expanded coverage of colorectal cancer screening procedures would generally lead to an increase in the number of colonoscopies performed over the next five years. There would also be a rise in the sales of devices used in the procedures, such as colonoscopes and biopsy forceps, to meet this growing demand for colorectal cancer screening.
Future Scenario
The colorectal cancer market in the US is expected to witness many changes in the future horizon. With new treatments improving the survival rates of patients, it would be of utmost importance to determine the optimal treatment for each patient. This is an indication of the therapy having a direct impact on the potential of revenue for drugs in this arena. With recent advances in targeted therapies and improvements in chemotherapy targeted towards improving lives of patients, continued innovation and product development is demanded, given the popularity of colorectal cancer in the US.
Among the drug classes, it is most likely that there would a decline in the market share of the EGFR inhibitor drug class from 2011 to 2021. The major reasons for this would be the strong competition in the biosimilars market and an increased use of angiogenesis inhibitors in the second-line setting which push the EGFR-targeted therapies into the smaller later-line treatment settings.
The continued improvements in screening would modify both the risk and stage distribution of diagnosed CRC over the next decade. With expected improvements in the survival rates, there would most likely be an increase in the number of people living with CRC over the next 20 years, despite the number developing the disease per year remaining relatively stable due to the combined effects of screening and forecast improvements in the management of disease recurrence.
New advances in products such as cytotoxic and targeted therapy drugs would changethe landscape of options and pathways utilized by physicians to fight the disease. The players in this market would be required to have a deep understanding of the demography in the country in judging market opportunities, both for existing product expansion and new product development.
